Stengone Carmine N.

Stengone Carmine N. is listed in filings as CEO and President at Contineum Therapeutics, Inc. Class A Common Stock. This profile follows SEC Form 4 activity through Feb 26, 2026, including sale activity and purchase activity. Recent filings connect the profile to Contineum Therapeutics, Inc. Class A Common Stock (CTNM) and Kiora Pharmaceuticals, Inc. (KPRX). The current snapshot covers public activity from Jul 3, 2024 to Feb 26, 2026. Reported amounts are shown as $3.4K to $70.5K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.